» Articles » PMID: 12135615

Adenoviral Overexpression of Apolipoprotein A-V Reduces Serum Levels of Triglycerides and Cholesterol in Mice

Overview
Publisher Elsevier
Specialty Biochemistry
Date 2002 Jul 24
PMID 12135615
Citations 51
Authors
Affiliations
Soon will be listed here.
Abstract

Mice lacking ApoA-V, a novel HDL-associated apolipoprotein identified by our group and independently by Pennacchio et al. [Science 294 (2001) 169], were recently shown to be hypertriglyceridemic. To study the role of ApoA-V in triglyceride homeostasis, we compared lipid profiles in mice expressing normal and highly elevated levels of ApoA-V. For this purpose, adenoviral vectors expressing sense or antisense ApoA-V cDNA were constructed. Treatment of mice with sense adenoviral constructs resulted in circa 20-fold higher serum ApoA-V levels compared with mice injected with either PBS or antisense adenoviral constructs. ApoA-V overexpressing mice had markedly decreased (-70%) serum triglyceride levels caused primarily by lowered triglyceride content of the VLDL fraction. Furthermore, in these mice cholesterol levels were found to be lowered in all lipoprotein fractions with the largest mass decrease in the HDL fraction. This resulted in a 40% drop of serum cholesterol content. These findings suggest a role of ApoA-V in regulating levels of circulating triglycerides and cholesterol.

Citing Articles

Macromolecular Interactions of Lipoprotein Lipase (LPL).

Wheless A, Gunn K, Neher S Subcell Biochem. 2024; 104:139-179.

PMID: 38963487 DOI: 10.1007/978-3-031-58843-3_8.


APOA5 deficiency causes hypertriglyceridemia by reducing amounts of lipoprotein lipase in capillaries.

Yang Y, Konrad R, Ploug M, Young S J Lipid Res. 2024; 65(7):100578.

PMID: 38880127 PMC: 11299584. DOI: 10.1016/j.jlr.2024.100578.


Understanding Hypertriglyceridemia: Integrating Genetic Insights.

Alves M, Laranjeira F, Correia-da-Silva G Genes (Basel). 2024; 15(2).

PMID: 38397180 PMC: 10887881. DOI: 10.3390/genes15020190.


Apolipoprotein A5 gene polymorphism (rs662799) and cardiovascular disease in end-stage kidney disease patients.

Jacob J, Boczkowska S, Zaluska W, Buraczynska M BMC Nephrol. 2022; 23(1):307.

PMID: 36071387 PMC: 9450442. DOI: 10.1186/s12882-022-02925-1.


Triglyceride and Triglyceride-Rich Lipoproteins in Atherosclerosis.

Zhang B, Yin F, Qiao Y, Guo S Front Mol Biosci. 2022; 9:909151.

PMID: 35693558 PMC: 9174947. DOI: 10.3389/fmolb.2022.909151.